Terns Pharmaceuticals Inc (NASDAQ: TERN) is -28.19% lower on its value in year-to-date trading and has touched a low of $1.87 and a high of $11.40 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TERN stock was last observed hovering at around $4.53 in the last trading session, with the day’s gains setting it 0.36%.
Currently trading at $4.89, the stock is 21.16% and 39.20% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.45 million and changing 7.95% at the moment leaves the stock 0.59% off its SMA200. TERN registered -11.73% loss for a year compared to 6-month loss of -14.96%. The firm has a 50-day simple moving average (SMA 50) of $3.5129 and a 200-day simple moving average (SMA200) of $4.8611.
The stock witnessed a 32.16% gain in the last 1 month and extending the period to 3 months gives it a 144.50%, and is 27.01% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.76% over the week and 8.75% over the month.
Terns Pharmaceuticals Inc (TERN) has around 59 employees, a market worth around $427.08M and $0.00M in sales. Distance from 52-week low is 162.20% and -57.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.65%).
The EPS is expected to shrink by -5.34% this year
190.0 institutions hold shares in Terns Pharmaceuticals Inc (TERN), with institutional investors hold 100.52% of the company’s shares. The shares outstanding are 87.30M, and float is at 66.38M with Short Float at 8.95%. Institutions hold 100.24% of the Float.
The top institutional shareholder in the company is ORBIMED ADVISORS LLC with over 7.62 million shares valued at $51.89 million. The investor’s holdings represent 10.2326 of the TERN Shares outstanding. As of 2024-06-30, the second largest holder is VIVO CAPITAL, LLC with 6.18 million shares valued at $42.11 million to account for 8.3038 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 6.1 million shares representing 8.1923 and valued at over $41.54 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 6.6448 of the shares totaling 4.95 million with a market value of $33.69 million.
Terns Pharmaceuticals Inc (TERN) Insider Activity
The most recent transaction is an insider sale by Kuriakose Emil, the company’s Chief Medical Officer. SEC filings show that Kuriakose Emil sold 853 shares of the company’s common stock on Jul 01 ’25 at a price of $4.27 per share for a total of $3640.0. Following the sale, the insider now owns 52464.0 shares.
Terns Pharmaceuticals Inc disclosed in a document filed with the SEC on Jun 27 ’25 that Gengos Andrew (Chief Financial Officer) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Jun 27 ’25 and was made at $3.93 per share for $39283.0. Following the transaction, the insider now directly holds 25000.0 shares of the TERN stock.
Still, SEC filings show that on Jun 25 ’25, Burroughs Amy L. (Chief Executive Officer) acquired 23,314 shares at an average price of $3.87 for $90230.0. The insider now directly holds 47,083 shares of Terns Pharmaceuticals Inc (TERN).
